METACARE to Absorb Wholly-Owned Subsidiary
메타케어
118000
Signal Score
Historical Avg Return (5d)
-0.14%
Data Coverage
100%n=675
Risk-adjusted indicator based on 675 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Acquisition Cost of JK Medi: 360M KRW
- • JK Medi 2025 Revenue: 3.79B KRW
- • JK Medi 2025 Net Income: 326.76M KRW
- • METACARE's Stake in JK Medi: 100%
- • Merger Date: October 1, 2026
AI Analysis Summary
METACARE Co., Ltd. announced a small-scale absorption merger with its wholly-owned subsidiary, JK Medi Co., Ltd., which was acquired for 360M KRW on July 27, 2026. The merger, effective October 1, 2026, aims to enhance operational efficiency and business competitiveness by eliminating unnecessary costs. As JK Medi is a 100% subsidiary, no new shares will be issued, and there will be no change in METACARE's capital or major shareholder structure. JK Medi reported 2025 revenue of 3.79B KRW and net income of 326.76M KRW. The financial impact on METACARE is expected to be minimal due to the existing full ownership. The merger will proceed without a shareholder meeting approval, subject to no more than 20% of shareholders opposing it.
How This Event Is Evaluated
M&A / Merger Evaluation
M&A events are evaluated by assessing deal size relative to company scale, strategic rationale, financing structure, and integration risk.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Deal size relative to market value
- Strategic fit and synergy potential
- Financing structure (cash, stock, debt)
- Regulatory and integration risk
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.